I agree that when your product makes it through the approval process, Physicians and patients will have more than one medicine to use for their ailment.

The more treatment options you come up with, the more costly it is to produce biosimilar products. Moreover, it becomes more complicated to assimilate them into the reference drug. How are you willing to advise your company on the expensive process of coming up with treatment options?